The Trump administration’s headline-grabbing move to slash the Unites States (US) prescription drug prices by up to 59% has sent shockwaves through the global pharmaceutical industry. While the policy is designed to make medicines more affordable for American patients, its ripple effects could fundamentally reshape the pharmaceutical markets-not only in the European Union (EU) and Japan, but also in the United Kingdom (UK), Australia, and key Asia-Pacific (APAC) economies-all regions known for their stringent drug pricing frameworks.
A Ripple Becomes a Global Wave
In the EU, drug prices are tightly regulated through reference pricing and health technology assessments (HTAs), ensuring broad access to cost-effective treatments. Japan employs a similar model, conducting biannual price revisions under its National Health Insurance (NHI) scheme. Both systems use international benchmarking-particularly referencing the US prices, which have historically served as the global high-water mark.
With the U.S. potentially losing its status as the world’s most lucrative pharmaceutical market, manufacturers may reevaluate where and how they launch new therapies. Analysts warn that companies could pressurize governments in other regions to soften price controls or else risk delayed launches or non-availability of innovative treatments, particularly orphan drugs that rely on premium pricing to recover development costs.
This scenario is not isolated to the EU and Japan. The UK, Australia, and APAC nations may face similar challenges and strategic recalibrations.
UK: Navigating NICE and Value-Based Care
The UK, through the National Institute for Health and Care Excellence (NICE), already uses robust HTA mechanisms to determine drug cost-effectiveness. NICE decisions directly influence whether the National Health Services (NHS) will reimburse medicine, with strict thresholds on quality-adjusted life years (QALYs) per pound spent.
With the US introducing substantial price controls, the UK may lose leverage when referencing global pricing. While the UK is well-positioned due to its strong tradition of evidence-based assessments and cost control, drugmakers may become less willing to launch new products in such tightly regulated environments unless pricing flexibility increases. The Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which caps NHS spending on branded drugs-may come under increasing scrutiny as firms push for more attractive returns.
Australia: PBS Under Pressure
Australia’s Pharmaceutical Benefits Scheme (PBS) is another benchmark system that negotiates drug prices centrally to ensure affordability and equitable access. Like the UK and EU, PBS relies on HTAs and reference pricing, often comparing Australian prices to those in countries like the US.
As the US price ceiling drops, pharmaceutical companies may demand renegotiation of existing price points in Australia or prioritize other markets for launching high-cost therapies. The Therapeutic Goods Administration (TGA) may also face mounting pressure to streamline regulatory timelines to maintain Australia’s attractiveness as an early-launch market.
APAC: Fragmented Markets, Common Challenges
The broader Asia-Pacific region presents a patchwork of pricing and reimbursement models. Countries like South Korea and Taiwan operate systems like Japan, with regular price revisions and HTAs. Meanwhile, emerging markets such as India, Indonesia, and the Philippines often rely on generics and have limited capacity to pay for high-cost innovations.
In South Korea, the Health Insurance Review & Assessment Service (HIRA) may need to revisit its pricing logic as global benchmarks shift. China, on the other hand, is undergoing a transformation, with its National Reimbursement Drug List (NRDL) and bulk procurement policies already exerting downward pressure on prices. However, multinational companies are still attracted by their volume potential.
As US pricing benchmarks fall, the APAC region may either benefit from greater negotiating power or face strategic deprioritization if pricing concessions are too complex for companies to sustain R&D and commercialization efforts.
The Executive Order: A Global Pricing Recalibration
The Trump administration’s executive order, signed in May 2025, directs pharmaceutical companies to reduce US drug prices to match those paid in other developed countries, with targets for reductions ranging from 59% to 90%. The order sets price benchmarks for drug manufacturers and threatens further measures, if these targets are not met. The “most favored nation” approach aims to end the practice of Americans paying the highest prices globally and to force foreign countries to pay more, potentially shifting the global pricing landscape.
While the directive has been welcomed by many Americans burdened by high medication costs, its implementation faces legal and practical challenges, and its immediate impact on consumer prices remains uncertain.
Data, Innovation, and Value-Based Models Across Regions
Globally, countries are gravitating toward value-based pricing, linking reimbursement to real-world outcomes. This trend is evident not just in the EU and Japan, but also in the UK (via NICE’s cost-per-QALY framework), Australia (through PBAC’s assessments), and even emerging APAC markets where pilot risk-sharing agreements are beginning to establish themselves.
However, disparities in infrastructure, particularly in real-world data (RWD) quality and regulatory readiness, remain a challenge-especially in emerging economies. Without robust RWD frameworks, many countries may struggle while making effective transitions to performance-based models.
A Crossroads for Global Pharma Policy
The new US pricing paradigm could serve as a catalyst for global reform or a crisis for regions reliant on reference pricing. Countries like the UK and Japan may try to reinforce premium pricing pathways to ensure innovation is rewarded. Meanwhile, Australia and APAC markets could explore international partnerships, shared databases, and joint procurement initiatives to strengthen bargaining positions and ensure equitable access.
Conclusion: The End of the Pricing Status Quo
The dramatic shift in drug pricing policy by the US is more than a domestic reform: it is a global disruptor. From the EU and Japan to the UK, Australia, and APAC, governments and health systems must confront a new reality: the high-price anchor is likely gone, and pharmaceutical companies will now pursue profitability across a more level (and less forgiving) global playing field.
Whether this new era leads to collaborative reform or contentious standoffs will depend on how effectively each region adapts its pricing, innovation, and access strategies. One thing is clear: in today’s interconnected pharmaceutical economy, what happens in Washington will reverberate in London, Tokyo, Canberra, and beyond.
